Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...
Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...
Clinical research is advancing quickly, but scientific momentum is colliding with persistent operational constraints. | Mike Novotny examines the funding, technology and operational challenges shaping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results